Barclays
IMUC

Barclays’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Barclays’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,120
Closed -$320K – 7976
2013
Q2 		$320K Buy
+4,120
New +$395K ﹤0.01% 4722

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Barclays's IMUC Position: Q4 2018 in Review

Barclays sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 50 shares.

Barclays first reported a position in IMUC in Q2 2013 and held it in 18 quarters. The position peaked at $352K in Q2 2013. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • Barclays reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • Barclays sold 50 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
  • Barclays first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 18 quarters.
  • Barclays's ImmunoCellular Therapeutics, Ltd. position peaked at $352K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.